Further, combined use of gefitinib and IRX4 knockdown significantly downregulated NANOG protein level in vitro, and markedly decreased tumor growth and the expression of NANOG and CD133 in vivo, than treatment with gefitinib alone. Here, IRX4 is linked to neoplasm.